<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>449</serviceExecutionTime><Drug id="5119"><DrugName>lenograstim</DrugName><DrugNamesKey><Name id="42824753">Granocyte</Name><Name id="42824703">Neutrogin</Name><Name id="42824702">lenograstim</Name></DrugNamesKey><DrugSynonyms><Name><Value>Myelostim</Value></Name><Name><Value>CSF, Chugai</Value></Name><Name><Value>G-CSF, AMRAD</Value></Name><Name><Value>G-CSF, Chugai</Value></Name><Name><Value>hG-CSF, Chugai</Value></Name><Name><Value>rHuG-CSF, Chugai</Value></Name><Name><Value>G-CSF, Rhone-Poulenc Rorer</Value></Name><Name><Value>lenograstim</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>Neutrogin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Granocyte</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15414">Chugai Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="14214">AMRAD Pharmaceuticals Pty Ltd</Company><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="15416">CHUGAI sanofi-aventis SNC</Company><Company id="19298">Rhone-Poulenc Rorer Ltd</Company><Company id="19365">Rhone-Poulenc Rorer Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="5119" type="Drug"><TargetEntity id="179047" type="siDrug">Lenograstim</TargetEntity></SourceEntity><SourceEntity id="14214" type="Company"><TargetEntity id="4296060162" type="organizationId">AMRAD Pharmaceuticals Private Ltd</TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="15416" type="Company"><TargetEntity id="4298162023" type="organizationId">Chugai Sanofi Aventis SNC</TargetEntity></SourceEntity><SourceEntity id="19298" type="Company"><TargetEntity id="5031714070" type="organizationId">Rhone-Poulenc Rorer Ltd</TargetEntity></SourceEntity><SourceEntity id="19365" type="Company"><TargetEntity id="5036165108" type="organizationId">Rhone-Poulenc Rorer Inc</TargetEntity></SourceEntity><SourceEntity id="142" type="ciIndication"><TargetEntity id="10061590" type="MEDDRA"></TargetEntity><TargetEntity id="D006402" type="MeSH"></TargetEntity><TargetEntity id="-1796155433" type="omicsDisease"></TargetEntity><TargetEntity id="987" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="185" type="ciIndication"><TargetEntity id="10021428" type="MEDDRA"></TargetEntity><TargetEntity id="D007154" type="MeSH"></TargetEntity><TargetEntity id="-155407498" type="omicsDisease"></TargetEntity><TargetEntity id="1128" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1991" type="ciIndication"><TargetEntity id="D70" type="ICD10"></TargetEntity><TargetEntity id="10029354" type="MEDDRA"></TargetEntity><TargetEntity id="D009503" type="MeSH"></TargetEntity><TargetEntity id="-506284464" type="omicsDisease"></TargetEntity><TargetEntity id="1002" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity></SourceEntity><SourceEntity id="PTGT-00800" type="ciTarget"><TargetEntity id="36485060414413" type="siTarget">Granulocyte colony-stimulating factor receptor</TargetEntity><TargetEntity id="276" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Neutropenia - Japan - Dec-1991</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="142">Hematological disease</Indication><Indication id="185">Immune disorder</Indication><Indication id="1991">Neutropenia</Indication></IndicationsPrimary><ActionsPrimary><Action id="3151">GCSF receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="393">Immunostimulant</Action><Action id="610">Hematopoietic stimulator</Action><Action id="7759">Neutrophil stimulator</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="112">DNA technology</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="746">Solution</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="127">Cell culture</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-22T11:05:04.000Z</LastModificationDate><ChangeDateLast>2019-06-19T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="15414" linkType="Company"&gt;Chugai Pharmaceutical&lt;/ulink&gt;, and marketed by Chugai and &lt;ulink linkID="1009547" linkType="Company"&gt;sanofi-aventis&lt;/ulink&gt; (formerly  &lt;ulink linkID="27254" linkType="Company"&gt;Aventis SA&lt;/ulink&gt;; now &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;) in select markets outside of the US, lenograstim (Granocyte; Neutrogin) is a glycosylated form of recombinant human granulocyte colony stimulating factor (rHuG-CSF) administered sc or by iv infusion. In the UK, the product is indicated for the reduction of the duration of neutropenia in patients (with non myeloid malignancy) undergoing myeloablative therapy followed by bone marrow transplantation (BMT) and considered to be at increased risk of prolonged severe neutropenia, for the reduction of the duration of severe neutropenia and its associated complications in patients undergoing established cytotoxic therapy associated with a significant incidence of febrile neutropenia, and for the mobilization of peripheral blood progenitor cells (PBPC) for patients as well as healthy donors [&lt;ulink linkID="1220704" linkType="Reference"&gt;1220704&lt;/ulink&gt;]. In Japan, lenograstim has been approved for neutropenia associated with chemotherapy of acute myeloid leukemia (AML), head and neck cancer, bladder tumor and breast cancer, and for  mobilization of hematopoietic stem cells into peripheral blood [&lt;ulink linkID="942705" linkType="Reference"&gt;942705&lt;/ulink&gt;], [&lt;ulink linkID="273348" linkType="Reference"&gt;273348&lt;/ulink&gt;], [&lt;ulink linkID="280557" linkType="Reference"&gt;280557&lt;/ulink&gt;], [&lt;ulink linkID="385168" linkType="Reference"&gt;385168&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 1991, lenograstim was launched in Japan for neutropenia, under the trade name Neutrogin [&lt;ulink linkID="942705" linkType="Reference"&gt;942705&lt;/ulink&gt;], [&lt;ulink linkID="1186966" linkType="Reference"&gt;1186966&lt;/ulink&gt;]. In January 1994, the product, as Granocyte, was launched in the UK for  neutropenia [&lt;ulink linkID="1220793" linkType="Reference"&gt;1220793&lt;/ulink&gt;]; later in 1994, it was launched elsewhere in the EU, including France, Germany and Italy [&lt;ulink linkID="1518631" linkType="Reference"&gt;1518631&lt;/ulink&gt;]. By March 1997, the EU label had been expanded for use in PBPC mobilization for autologous transplantation where it is marketed under the trade name Granocyte [&lt;ulink linkID="1220970" linkType="Reference"&gt;1220970&lt;/ulink&gt;]; in October 2000, approval for this indication was granted in Japan [&lt;ulink linkID="385168" linkType="Reference"&gt;385168&lt;/ulink&gt;], [&lt;ulink linkID="1137743" linkType="Reference"&gt;1137743&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In April 2004, &lt;ulink linkID="13794" linkType="Company"&gt;Ajinomoto Co Inc&lt;/ulink&gt; filed an appeal stating that Neutrogin, manufactured and sold by Chugai, infringed a process patent held by Ajinomoto. By December 2004, a trial was underway. At this time, Chugai asserted that there was no infringment [&lt;ulink linkID="598320" linkType="Reference"&gt;598320&lt;/ulink&gt;]. The product patent for lenograstim was based on WO-08604605. The Japanese equivalent to WO-08604605 was JP-02005395 which had received patent extensions with the longest being for 5 years thus extending the patent expiry date for the JP product patent to July 17, 2011. The equivalent EP expired February 7, 2006. However, an SPC had been granted on the Irish equivalent, and did not expire until July 28, 2008. US-04833127, expired May 23, 2006, and was recorded as a general interest patent by TS patent analysts, also had claims regarding lenograstim. The JP equivalent to &lt;ulink linkID="IN1473189" linkType="Patent"&gt;US-04833127&lt;/ulink&gt; had received an extension and was to expire on July 25, 2009, Similarly, the European equivalent, EP-00169566, has been granted SPCs for lenograstim in the UK and most other EU states and these were to expire by either June or July 2008 [&lt;ulink linkID="651776" linkType="Reference"&gt;651776&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2011, several generic lenograstim products were available in Germany [&lt;ulink linkID="1194066" linkType="Reference"&gt;1194066&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2013, Chugai noted that follow-on biologics of lenograstim were available [&lt;ulink linkID="1445032" linkType="Reference"&gt;1445032&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September and November 1993, respectively, lenograstim was approved in France and the UK for the reduction of neutropenia and associated complications in cancer patients undergoing chemotherapy and bone marrow transplantation for non-myeloid malignancies [&lt;ulink linkID="1220704" linkType="Reference"&gt;1220704&lt;/ulink&gt;], [&lt;ulink linkID="1220735" linkType="Reference"&gt;1220735&lt;/ulink&gt;], [&lt;ulink linkID="1220798" linkType="Reference"&gt;1220798&lt;/ulink&gt;]; in January 1994, the product was launched in the UK by European licensee &lt;ulink linkID="19365" linkType="Company"&gt;Rhone-Poulenc Rorer&lt;/ulink&gt; (subsequently Aventis, now &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;) [&lt;ulink linkID="1220793" linkType="Reference"&gt;1220793&lt;/ulink&gt;]; later in 1994, it was launched elsewhere in the EU, including France, Germany and Italy [&lt;ulink linkID="1518631" linkType="Reference"&gt;1518631&lt;/ulink&gt;]. By March 1997, lenograstim had also been granted approval in the EU under the Mutual Recognition Procedure for use in PBPC mobilization for autologous transplantation. The marketing authorization was granted through the EMA on the basis of several studies using lenograstim for PBPC mobilization; it is assumed that the product was launched for this indication shortly after approval. By that time, Lenograstim had also been approved for use in many additional countries, such as Norway, Switzerland and Russia [&lt;ulink linkID="177784" linkType="Reference"&gt;177784&lt;/ulink&gt;], [&lt;ulink linkID="598320" linkType="Reference"&gt;598320&lt;/ulink&gt;], [&lt;ulink linkID="1220970" linkType="Reference"&gt;1220970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;Lenograstim was first launched in Japan in 1991 [&lt;ulink linkID="942705" linkType="Reference"&gt;942705&lt;/ulink&gt;], [&lt;ulink linkID="1186966" linkType="Reference"&gt;1186966&lt;/ulink&gt;]. Lenograstim has been approved for neutropenia associated with chemotherapy of AML, head and neck cancer, bladder tumor and breast cancer  [&lt;ulink linkID="942705" linkType="Reference"&gt;942705&lt;/ulink&gt;], [&lt;ulink linkID="244822" linkType="Reference"&gt;244822&lt;/ulink&gt;],  [&lt;ulink linkID="273348" linkType="Reference"&gt;273348&lt;/ulink&gt;],  [&lt;ulink linkID="280557" linkType="Reference"&gt;280557&lt;/ulink&gt;]. In October 1999, Chugai filed for PBPC [&lt;ulink linkID="352587" linkType="Reference"&gt;352587&lt;/ulink&gt;], and in October 2000, Chugai announced that it had received approval for two changes to the indication for lenograstim: the addition of 'mobilization of hematopoietic stem cells into peripheral blood' and a change to 'promotion of increases in neutrophils at the time of hematopoietic stem cell transplantation' [&lt;ulink linkID="385168" linkType="Reference"&gt;385168&lt;/ulink&gt;], [&lt;ulink linkID="1137743" linkType="Reference"&gt;1137743&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;By May 1994, lenograstim had been launched in China [&lt;ulink linkID="177784" linkType="Reference"&gt;177784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt; By March 1997, approval had been granted in Brazil  for neutropenia and PBPC mobilization for autologous transplantation [&lt;ulink linkID="1220970" linkType="Reference"&gt;1220970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By March 1997, approval had been granted in  Israel for neutropenia and PBPC mobilization for autologous transplantation [&lt;ulink linkID="1220970" linkType="Reference"&gt;1220970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By May 1994, lenograstim had been launched in  South Korea for neutropenia [&lt;ulink linkID="177784" linkType="Reference"&gt;177784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 1998, licensee &lt;ulink linkID="14214" linkType="Company"&gt;AMRAD Pharmaceuticals&lt;/ulink&gt; (now a subsidiary of &lt;ulink linkID="1043009" linkType="Company"&gt;Merck Sharp &amp;amp; Dohme&lt;/ulink&gt; (Australia); a subsidiary of &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;) had launched lenograstim in New Zealand for neutropenia and PBPC mobilization [&lt;ulink linkID="1221220" linkType="Reference"&gt;1221220&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Neutropenia&lt;/subtitle&gt;By 1997, a multicenter, open-label phase II study had been conducted on 19 pediatric patients with chronic severe neutropenia. Lenograstim administration resulted in a median neutrophil recovery rate of 7 days after the start of treatment. Seven of 17 evaluated patients were able to tolerate double doses of the drug on alternate days. This significantly reduced incidence of infection and reduced hospitalization rates due to infection. Four patients discontinued treatment, but only one discontinuation was due to adverse events (thrombocytopenia, splenomegaly, anemia, bone pain and elevated alkaline phosphatase levels). Three patients had spontaneous neutrophil recovery after 9, 15 and 27 months [&lt;ulink linkID="1387154" linkType="Reference"&gt;1387154&lt;/ulink&gt;], [&lt;ulink linkID="274489" linkType="Reference"&gt;274489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peripheral blood progenitor cell mobilization&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By November 1998, a multicenter phase III study was conducted in 90 patients with Hodgkin's and non-Hodgkin's lymphoma who were treated with ablative chemotherapy (BEAM). The median neutrophil recovery time was 9 days in the lenograstim group compared with 13 days for the no growth factor arm. The median hospital stay was 13 days in patients treated with lenograstim compared with 15.5 days for those without. The trial showed that lenograstim in combination with cyclophosamide when administered daily was an effective regimen for mobilization of progenitor cells in lymphoma patients. In addition, daily lenograstim administration post high-dose chemotherapy and reinfusion of PBPCs, reduced the period of neutropenia and hospitalization [&lt;ulink linkID="1221220" linkType="Reference"&gt;1221220&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By November 1998, an open-label phase II study had been conducted to assess the efficacy of lenograstim compared with lenograstim plus chemotherapy for PBPC in advanced breast cancer patients (n = 24) following standard or intensified induction. The maximum progenitor cell mobilization was between 6 and 7.5 days for lenograstim patients compared with 11 and 13 days for the lenograstim plus chemotherapy group. The study demonstrated lenograstim's ability to mobilize progenitor cells; however more colony-forming cells were mobilized in the lenograstim plus chemotherapy arm [&lt;ulink linkID="1221220" linkType="Reference"&gt;1221220&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from an open-label phase II study assessing the ability of reinfused lenograstim-primed PBPC with lenograstim post chemotherapy to facilitate platelet recovery in breast cancer patients (n = 21) were reported. The peak levels of CD34+ cells and GM-CFC were 32 x106/l and 7.2 x105/l, respectively for patients administered lenograstim only at day 6, which confirmed that lenograstim (150 microg/m2/day) achieved mobilization of progenitor cells. However, lenograstim plus chemotherapy yielded higher progenitor cell levels, which declined following repeated chemotherapy administration [&lt;ulink linkID="1221220" linkType="Reference"&gt;1221220&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;By May 1994, in patients with neutropenia induced by chemotherapy treatment for malignant lymphomas, acute lymphocytic leukemia, lung and ovarian cancer, testicular tumors and neuroblastomas, lenograstim effectively elevated neutrophil counts, reducing duration of neutropenia and accelerating recovery of neutrophil counts. The drug is also indicated for neutropenia associated with bone marrow transplants, aplastic anemia and myelodysplastic syndrome [&lt;ulink linkID="177784" linkType="Reference"&gt;177784&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Lenograstim is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells [&lt;ulink linkID="1220704" linkType="Reference"&gt;1220704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14214">AMRAD Pharmaceuticals Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-11-30T00:00:00.000Z</StatusDate><Source id="1221220" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-17T00:00:00.000Z</StatusDate><Source id="1220793" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-05-23T00:00:00.000Z</StatusDate><Source id="177784" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-05-23T00:00:00.000Z</StatusDate><Source id="177784" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-01T00:00:00.000Z</StatusDate><Source id="244822" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14214">AMRAD Pharmaceuticals Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-11-30T00:00:00.000Z</StatusDate><Source id="1221220" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1991-12-31T00:00:00.000Z</StatusDate><Source id="942705" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-31T00:00:00.000Z</StatusDate><Source id="1137743" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19298">Rhone-Poulenc Rorer Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19298">Rhone-Poulenc Rorer Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="407847" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-31T00:00:00.000Z</StatusDate><Source id="1137743" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15416">CHUGAI sanofi-aventis SNC</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15416">CHUGAI sanofi-aventis SNC</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15416">CHUGAI sanofi-aventis SNC</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1518631" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15416">CHUGAI sanofi-aventis SNC</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-17T00:00:00.000Z</StatusDate><Source id="1220793" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1993-11-30T00:00:00.000Z</StatusDate><Source id="1220704" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1993-11-30T00:00:00.000Z</StatusDate><Source id="1220704" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-10-01T00:00:00.000Z</StatusDate><Source id="352587" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-08-30T00:00:00.000Z</StatusDate><Source id="165437" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-17T00:00:00.000Z</StatusDate><Source id="1220793" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1993-09-20T00:00:00.000Z</StatusDate><Source id="1220798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19298">Rhone-Poulenc Rorer Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19298">Rhone-Poulenc Rorer Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="142">Hematological disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-03-24T00:00:00.000Z</StatusDate><Source id="1220970" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00800"><Name>GCSF receptor</Name><SwissprotNumbers><Swissprot>P40223</Swissprot><Swissprot>Q99062</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2149617" linkType="reference" linkID="2149617"&gt;2149617&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1036094">Evonik Industries AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="112629" title="RPR GmbH and ASTA Medica to co-promote docetaxel, lenograstim and irinotecan in Germany"></Deal><Deal id="113138" title="AMRAD to manufacture Chugai's lenograstim"></Deal><Deal id="113141" title="Rhone-Poulenc to market Chugai's lenograstim in Europe  "></Deal></Deals><PatentFamilies><PatentFamily id="1084726" number="MX-2008002448" title="Method for purifying recombinant proteins with acid isoforms."></PatentFamily><PatentFamily id="1105880" number="WO-00222163" title="Remedies for ischemic diseases"></PatentFamily><PatentFamily id="126105" number="WO-2009042910" title="SHIP inhibition to direct hematopoietic stem cells and induce extramedullary hematopoiesis"></PatentFamily><PatentFamily id="1344543" number="WO-08604605" title="Human Granulocyte Colony Stimulating Factor"></PatentFamily><PatentFamily id="1497173" number="EP-00169566" title="Novel CSF and method for obtaining the same."></PatentFamily><PatentFamily id="1645276" number="EP-00217404" title="Pharmaceutical Composition Containing A Human Granulocyte Colony Stimulating Factor For The Treatment Of Leukopenia"></PatentFamily><PatentFamily id="1719753" number="EP-00231819" title="Pharmaceutical agent for the treatment of myelogenous leukemia"></PatentFamily><PatentFamily id="2050957" number="WO-00117542" title="Protein Solution Preparation And Method Of Stabilizing The Same"></PatentFamily><PatentFamily id="2587825" number="WO-2013129936" title="Use of an antibody and a particulate immunomodulator in therapy"></PatentFamily><PatentFamily id="2588049" number="WO-2013129935" title="Use of a particulate immunomodulator in cancer therapy"></PatentFamily><PatentFamily id="3470829" number="WO-2016191811" title="Mobilizing agents and uses therefor"></PatentFamily><PatentFamily id="3533307" number="WO-2017017187" title="Colony stimulating factor for use in pancreatic or colon cancer treatment"></PatentFamily><PatentFamily id="387384" number="GB-02193631" title="Stable Pharmaceutical Preparation."></PatentFamily><PatentFamily id="422734" number="WO-00217957" title="Solution preparations stabilized over long time"></PatentFamily><PatentFamily id="527893" number="WO-2012136829" title="Novel combination treatment of cancer"></PatentFamily><PatentFamily id="681948" number="EP-00355811" title="Thrombus control agent."></PatentFamily><PatentFamily id="830744" number="EP-00230980" title="Pharmaceutical agent for promoting the recovery of hemopoietic capacity"></PatentFamily><PatentFamily id="904928" number="EP-00220520" title="Human Granulocyte Colony Stimulating Factor"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Evonik Industries AG" id="1036094"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endor Nanotechnologies SL" id="1071315"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lipotarg GmbH" id="1073913"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cryopharma S A De C V Lab" id="1081632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IC Targets AS" id="1105864"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CSL Ltd" id="15563"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Italfarmaco SpA" id="17278"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>14</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Queensland" id="20665"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of South Florida" id="20677"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Basel" id="25177"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Claude Bernard Lyon 1" id="31153"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospices Civils De Lyon" id="31155"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Linde AG" id="DOL1000490"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>